Establishment of rhizoma smilacis glabrae HPLC fingerprint spectrum and antioxidant activity spectrum effect analysis method
By establishing the HPLC fingerprint and spectral analysis method of the wild yam, the epicatechin, neo-isotropin and other ingredients were identified as the main antioxidant components of the wild yam, which solved the problem of unclear antioxidant components in the wild yam. , provides a basis for quality control and development and utilization of Chinese yam medicinal materials.
Patent Information
- Application Number
- CN202411397735.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-08
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art has not yet identified the specific components of wild yam that play an antioxidant role, and there is a lack of a systematic analysis method for the quality of wild yam medicinal materials.
By establishing the HPLC fingerprint of wild yam, combining multiple spectral effect analysis methods, such as clustering analysis, principal component analysis, gray correlation analysis and partial least squares regression, antioxidant active ingredient groups, including epicatechin, Neo-Free and Neo-Free.
The antioxidant active ingredient group in yam was successfully identified, providing a reference basis for the quality control and development and utilization of yam medicinal materials, and improving the quality evaluation system of yam medicinal materials.
Smart Images

Figure CN119044368A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of traditional Chinese medicine analysis, and specifically relates to the establishment of a HPLC fingerprint of Smilax glabra and an antioxidant activity spectrum analysis method. Background Art
[0002] Smilax glabra is the dried rhizome of Smilax glabra Roxb., a plant of the Liliaceae family. It is sweet, light, and neutral in nature. It enters the liver and stomach meridians. It is also known as Prickly Polyporus, Mountain Dragon, and Fairy Residual Grain. It grows mostly on hillsides, barren mountains, and semi-shaded areas by the edge of forests. It is rich in resources and widely distributed in Hunan, Yunnan, Guangxi, and other places in my country. It has the effects of detoxification, dehumidification, and joint clearance. It is used for damp-heat stranguria, leucorrhea, carbuncle, scrofula, scabies, syphilis, and mercury poisoning caused by limb cramps, tendon and bone pain, etc. The main components of Smilax glabra are flavonoids, phenylpropanoids, steroids, organic acids, volatile oils, etc. Modern pharmacological studies have shown that Smilax glabra has antioxidant, immunosuppressive, anti-inflammatory, cardiovascular system protection, anti-tumor, and antibacterial effects.
[0003] Fingerprints combined with chemical pattern recognition have been widely used in the quality control of traditional Chinese medicines, and can more objectively reflect the quality of traditional Chinese medicines as a whole, and are an important means for evaluating the quality of medicinal materials. Chinese medicine spectrum-effect analysis combines chemical fingerprint information with drug efficacy evaluation, explores the mutual law between "spectrum" and "effect", and clarifies the composition and activity contribution degree of effective ingredients. At present, there are studies on the antioxidant activity of polysaccharides, total flavonoids, leaves and seeds in Smilax glabra, but there is no research report on the spectrum-effect relationship of Smilax glabra, and the specific contribution components that play an antioxidant role in Smilax glabra are still unclear. Therefore, the present invention is by establishing the HPLC fingerprint of Smilax glabra, and determining its in vitro antioxidant activity, taking fingerprints and antioxidant activity as the entry point for the first time, combining multiple spectrum-effect analysis methods to screen the antioxidant active ingredient group of Smilax glabra, for perfecting the quality evaluation system and development and utilization of Smilax glabra medicinal materials provide a reference basis. Summary of the invention
[0004] The present invention provides an HPLC fingerprint of a Chinese smilax glabra medicinal material, characterized in that when the HPLC chromatographic conditions are as follows, the HPLC fingerprint of the Chinese smilax glabra medicinal material is substantially the same as Figure 1 Consistency;
[0005] HPLC chromatographic conditions are as follows:
[0006] The chromatographic column is Agilent 5TC-C 18 , specifications: 250mm×4.6mm, 5μm;
[0007] Mobile phase: acetonitrile as phase A, 0.05wt% phosphoric acid aqueous solution as phase B;
[0008] Gradient elution: 0-16 min, phase A volume percentage of 6% → 14%; 16-28 min, phase A volume percentage of 14% → 16%, 28-32 min, phase A volume percentage of 16%, 32-42 min, phase A volume percentage of 16% → 18%; 42-48 min, phase A volume percentage of 18%, 48-56 min, phase A volume percentage of 18% to 23%, 56-62 min, phase A volume percentage of 23%, 62-70 min, phase A volume percentage of 23% to 30%, 70-80 min, phase A volume percentage of 30%; flow rate: 0.8 mL min -1 ; Column temperature: 30℃; Detection wavelength: 220nm; Injection volume: 10μL.
[0009] Another embodiment of the present invention provides the HPLC fingerprint of the above-mentioned Smilax glabra medicinal material, characterized in that the HPLC fingerprint of the Smilax glabra medicinal material is substantially the same as Figure 1 The results of the present invention are consistent with those of the above-mentioned compounds, with no less than 19 characteristic fingerprint chromatographic peaks, among which peak 2 is catechin, peak 6 is epicatechin, peak 8 is 5-O-caffeoylshikimic acid, peak 12 is neoastilbin, peak 13 is astilbin, peak 15 is neoisoastilbin, peak 16 is isoastilbin, peak 17 is flavopidine and peak 18 is resveratrol.
[0010] Another embodiment of the present invention provides an HPLC fingerprint of the above-mentioned Smilax glabra medicinal material, characterized in that the relative retention times of peaks 2, 6, 12, 13, 15, 16, 17, and 18 in the HPLC fingerprint of the Smilax glabra medicinal material are shown in the following table, taking the retention time of peak 8 as a reference:
[0011]
[0012] Another embodiment of the present invention provides the application of the HPLC fingerprint of the above-mentioned Smilax glabra medicinal material in the quality control and component analysis of the Smilax glabra medicinal material.
[0013] Another embodiment of the present invention provides the application of the HPLC fingerprint of the above-mentioned Smilax glabra medicinal material in the quality control of the Smilax glabra medicinal material, characterized in that the application comprises the following steps:
[0014] (1) crushing the Chinese smilax glabra medicinal material and then ultrasonically extracting it to prepare a test solution;
[0015] (2) Take the test sample solution obtained in step (1) and perform HPLC detection to obtain an HPLC chart of the test sample, wherein the chromatographic conditions are as follows:
[0016] The chromatographic column is Agilent 5TC-C 18, specifications: 250mm×4.6mm, 5μm;
[0017] Mobile phase: acetonitrile as phase A, 0.05wt% phosphoric acid aqueous solution as phase B;
[0018] Gradient elution: 0-16 min, phase A volume percentage of 6% → 14%; 16-28 min, phase A volume percentage of 14% → 16%, 28-32 min, phase A volume percentage of 16%, 32-42 min, phase A volume percentage of 16% → 18%; 42-48 min, phase A volume percentage of 18%, 48-56 min, phase A volume percentage of 18% to 23%, 56-62 min, phase A volume percentage of 23%, 62-70 min, phase A volume percentage of 23% to 30%, 70-80 min, phase A volume percentage of 30%; flow rate: 0.8 mL min -1 ; Column temperature: 30°C; Detection wavelength: 220nm; Injection volume: 10μL;
[0019] (3) Compare the HPLC chromatogram of the test sample obtained in step (2) with the HPLC fingerprint of the Smilax glabra medicinal material described in the present invention, and the Smilax glabra medicinal material with a similarity of more than 0.81 is a qualified product. The Smilax glabra medicinal material with a similarity of more than 0.95 is a high-quality product.
[0020] The preparation method of the test solution described in step (1) is as follows: grind the Chinese smilax glabra medicinal material, pass it through a 40-mesh sieve, weigh 0.5 g, place it in a stoppered conical flask, accurately add 10 ml of 70% by volume methanol, plug it tightly, weigh it, treat it with ultrasound for 30 minutes, let it stand and cool to room temperature, weigh it again, make up the weight loss with 70% by volume methanol, shake it well, filter it, and pass the filtrate through a 0.45 μm microporous filter membrane to obtain the product.
[0021] The Chinese smilax glabra medicinal material described in the present invention refers to Chinese smilax glabra decoction pieces.
[0022] Compared with the prior art, the advantages of the present invention are: (1) the present invention establishes a fingerprint of Smilax glabra medicinal materials through HPLC analysis of Smilax glabra medicinal materials samples from different origins, thereby providing an effective method for quality control of Smilax glabra medicinal materials; (2) by analyzing the HPLC spectra of 40 batches of Smilax glabra medicinal materials from different origins, the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" (2012 Edition) is used to determine the common pattern of the HPLC fingerprint of Smilax glabra medicinal materials, and 19 common peaks are calibrated, among which peak 2 is catechin, peak 6 is epicatechin, peak 8 is 5-O-caffeoylshikimic acid, peak 12 is neoastilbin , peak 13 is astilbin, peak 15 is neoisoastilbin, peak 16 is isoastilbin, peak 17 is flavonoids, and peak 18 is resveratrol; (3) The samples of Smilax glabra were preliminarily evaluated by cluster analysis (HCA) and principal component analysis (PCA). The antioxidant activity of the samples was evaluated by different test methods, and the spectrum-effect relationship of Smilax glabra was established by grey correlation analysis (GRA) and partial least squares regression (PLSR) analysis. It was found that epicatechin, neoisoastilbin, isoastilbin and other components were highly correlated with antioxidant activity indicators, and may be the key components of the antioxidant effect of Smilax glabra. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is the HPLC chart of Smilax glabra sample;
[0024] Figure 2 It is the superposition and comparison of HPLC fingerprints of 40 batches of Smilax glabra samples;
[0025] Figure 3 HPLC charts of Smilax glabra (A) and mixed reference substance (B); Notes: 2. Catechin; 6. Epicatechin; 8. 5-O-caffeoylshikimic acid; 12. Neoastilbin; 13. Astilbin; 15. Neoisoastilbin; 16. Isoastilbin; 17. Folium sibiricum glycoside; 18. Resveratrol.
[0026] Figure 4 This is the clustering heat map of 40 batches of Smilax glabra;
[0027] Figure 5 This is the scatter plot of principal component analysis of 40 batches of Smilax glabra.
[0028] Figure 6 This is the partial least square regression coefficient diagram of each common peak of Smilax glabra of the present invention;
[0029] Figure 7 It is the antioxidant VIP value of each common peak of Smilax glabra of the present invention. DETAILED DESCRIPTION
[0030] 1 Materials
[0031] 1.1 Instruments
[0032] Agilent 1260 high performance liquid chromatograph (Agilent Technologies, Inc., USA); KQ5200DE numerically controlled ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.); DFT-200A portable high-speed pulverizer (Wenling Linda Machinery Co., Ltd.); BT25S electronic analytical balance (d = 0.01 mg), BS210S electronic analytical balance (d = 0.1 mg) (Beijing Sartorius Balance Co., Ltd.); MULTISKAN Sky microplate reader (Thermo Fisher Scientific, USA).
[0033] 1.2 Reagents and drugs
[0034] The reference substances astilbin (batch number: CHB201131), 5-O-caffeoylshikimic acid (batch number: CHB230906), and resveratrol (batch number: CHB201107) were purchased from Chengdu Kroma Biotechnology Co., Ltd. (purity ≥ 98%); catechin (batch number: 18061201) was purchased from Shanghai Qiming Biotechnology Co., Ltd. (purity ≥ 98%); cyperidin (batch number: 111906-202303) was purchased from Shanghai Qiming Biotechnology Co., Ltd. (purity ≥ 98%). ) was purchased from the China Food and Drug Inspection Institute (purity ≥ 93.6%); neoisastilbin (batch number: HR4164W2), neoastilbin (batch number: HR4163W4), isostilbin (batch number: HR5453W2), and epicatechin (batch number: HR15126S1) were all purchased from Baoji Chenguang Biotechnology Co., Ltd. (purity ≥ 98%); methanol and acetonitrile were chromatographically pure (ThermoFisher, USA) Scientific Company); 2,2-biphenyl-1-picrylhydrazyl (DPPH, batch number: C16266521) was purchased from Shanghai MacLean Biochemical Technology Co., Ltd.; vitamin C (VC, batch number: D01GB169601) was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (purity ≥ 98%); 2,2-azino-bis(3-ethyl-benzothiazole-6-sulfonic acid) diammonium salt (ABTS) scavenging ability kit (batch number: 20240716) was purchased from Nanjing Jiancheng Bioengineering Institute. Water was ultrapure water, and other reagents were of analytical grade.
[0035] The 40 batches of Smilax glabra slices were identified by Zhang Hong, a researcher at Shaanxi Institute of Traditional Chinese Medicine, as the dried rhizomes of Smilax glabra Roxb., a plant of the Liliaceae family. The sample source information is shown in Table 1.
[0036] Table 1 Information of Smilax glabra samples
[0037]
[0038] 2 Methods and Results
[0039] 2.1 Chromatographic conditions
[0040] Using Agilent 5TC-C 18 (2) (250 mm × 4.6 mm, 5 μm) chromatographic column; acetonitrile (A)-0.05% phosphoric acid aqueous solution (B) as mobile phase, elution gradient (0-16 min, 6%-14% A; 16-28 min, 14%-16% A; 28-32 min, 16% A; 32-42 min, 16%-18% A; 42-48 min, 18% A; 48-56 min, 18%-23% A; 56-62 min, 23% A; 62-70 min, 23%-30% A; 70-80 min, 30% A), column temperature 30°C, injection volume 10 μL, flow rate 0.8 mL min -1 , the detection wavelength is 220nm.
[0041] 2.2 Preparation of reference solution
[0042] Accurately weigh appropriate amounts of reference substances catechin, epicatechin, 5-O-caffeoylshikimic acid, neoastilbin, astilbin, neoisoastilbin, isoastilbin, flavonoids glycoside, and resveratrol, dissolve them in 70% methanol and make up to volume to prepare solutions with mass concentrations of 0.3, 0.45, 0.3, 0.4, 0.4, 0.45, 0.2, 0.45, and 0.2 mg·mL, respectively. -1 of mixed reference solution.
[0043] 2.3 Preparation of test solution
[0044] Accurately weigh 0.5 g of Smilax glabra powder (passed through a 40-mesh sieve), place in a stoppered conical flask, accurately add 10 ml of 70% by volume methanol, stopper, weigh, ultrasonicate for 30 min, let stand and cool to room temperature, weigh again, make up for the weight loss with 70% by volume methanol, shake well, filter, and pass the filtrate through a 0.45 μm microporous filter membrane to obtain the product.
[0045] 2.4 Methodological Review
[0046] 2.4.1 Precision test
[0047] Take an appropriate amount of sample S1, prepare the test solution according to the method under "2.3", inject the sample 6 times continuously according to the chromatographic conditions under "2.1", and record the chromatogram. Take peak 8 5-O-caffeoylshikimic acid as the reference peak (S), calculate the relative retention time and relative peak area RSD of each common peak (see Table 2 and Table 3). The results show that the relative retention time RSD of each common peak is 0.17% to 0.31%, and the relative peak area RSD is 0.76% to 4.61%, indicating that the instrument has good precision.
[0048] Table 2 Relative retention time of precision test
[0049]
[0050] Table 3 Relative peak area of precision test
[0051]
[0052] 2.4.2 Repeatability test
[0053] Take 6 portions of sample S1, prepare the test solution in parallel according to the method under "2.3", inject and measure according to the chromatographic conditions under "2.1", and record the chromatogram. Take peak 8 5-O-caffeoylshikimic acid as the reference peak (S), calculate the relative retention time and relative peak area RSD of each common peak (see Table 4 and Table 5). The results show that the relative retention time RSD of each common peak is 0.22% to 0.40%, and the relative peak area RSD is 0.80% to 4.90%, indicating that the method has good repeatability.
[0054] Table 4 Relative retention time of repeatability test
[0055]
[0056] Table 5 Relative peak area of repeatability test
[0057]
[0058] 2.4.3 Stability test
[0059] Take an appropriate amount of sample S1, prepare the test solution according to the method under "2.3", and inject and measure at 0, 2, 4, 6, 8, 12, and 24 hours according to the chromatographic conditions under "2.1", and record the chromatogram. Take peak 8 5-O-caffeoylshikimic acid as the reference peak (S), calculate the relative retention time and relative peak area RSD of each common peak (see Table 6 and Table 7). The results show that the relative retention time RSD of each common peak is 0.07% to 0.20%, and the relative peak area RSD is 0.68% to 4.79%, indicating that the test solution is stable within 24 hours.
[0060] Table 6 Relative retention time of stability test
[0061]
[0062] Table 7 Relative peak area of stability test
[0063]
[0064]
[0065] 2.5 Establishment and similarity evaluation of HPLC fingerprint of Smilax glabra
[0066] 2.5.1 Similarity Evaluation
[0067] Take 40 batches of Smilax glabra samples, weigh them accurately, prepare the test solution according to the method in "2.3", and then inject and measure according to the chromatographic conditions in "2.1", and record the chromatogram (see Figure 1 The data were imported into the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" (2012 Edition) for analysis. The chromatogram of sample S1 was used as the reference spectrum, the time window width was 0.1, the average method was used, and Mark peak matching was used after multi-point correction to generate HPLC superimposed fingerprints and reference spectra (R) of 40 batches of Smilax glabra samples. A total of 19 common peaks were calibrated ( Figure 2 ). After comparing the retention times of the test sample and the reference sample, 9 common peaks were identified, of which peak 2 was catechin, peak 6 was epicatechin, peak 8 was 5-O-caffeoylshikimic acid, peak 12 was neoastilbin, peak 13 was astilbin, peak 15 was neoisoastilbin, peak 16 was isoastilbin, peak 17 was flavonoids, and peak 18 was resveratrol ( Figure 3 ). With the reference fingerprint R as reference, the software was used to calculate the similarity between 40 batches of Smilax glabra and the reference fingerprint. The results showed that except for S6, S7, S36, and S40, whose similarities were 0.206, 0.174, 0.572, and 0.358, the similarities between the remaining batches of samples and the reference fingerprint were all greater than 0.811, as shown in Table 8, indicating that there are certain differences in the quality of Smilax glabra from different origins.
[0068] Table 8 Similarity of HPLC fingerprints of 40 batches of Smilax glabra
[0069]
[0070]
[0071] 2.5.2 Hierarchical cluster analysis (HCA)
[0072] The common peak area of 40 batches of Smilax glabra was used as the variable, and after Z standardization, it was imported into SPSS27.0 software. The inter-group linkage system clustering method was used to perform cluster analysis with squared Euclidean distance as the interval. The results are shown in Figure 4 When the square Euclidean distance was 10, the 40 batches of Smilax glabra samples were clustered into two categories: S1-S7, S12-S15, S19-S23, S25, S29, S30, S32-S36, S38, and S40 were clustered into category I, and S8-S11, S16-S18, S24, S26-S28, S31, S37, and S39 were clustered into category II.
[0073] 2.5.3 Principal component analysis (PCA)
[0074] SIMCA-P 14.1 software was used to perform unsupervised PCA with the peak areas of 19 common peaks of 40 batches of Smilax glabra samples as the X variable and the sample batch as the Y variable. The eigenvalues and variance contribution of the correlation coefficient were calculated. The eigenvalues of the first three principal components (PC1-PC3) were all >1, indicating that the first three principal components dominated the PCA analysis.
[14] The cumulative variance contribution rate reached 90.7%, which can represent most of the chemical information in the Chinese smilax glabra. The results are shown in Table 9. The information represented by the first three principal components obtained by PCA was plotted and analyzed. Figure 5 It can be seen that there is a certain separation trend of Smilax glabra from different origins, indicating that there are certain differences in the quality of Smilax glabra from different sources. The spatial distribution of 40 batches of Smilax glabra can be divided into two groups, among which S1-S7, S12-S15, S19-S23, S25, S29, S30, S32-S36, S38, and S40 are relatively close in distribution, and the distribution of the remaining batches is relatively close, which is basically consistent with the HCA results.
[0075] Table 9 Principal component eigenvalues and variance contribution rates
[0076]
[0077] 2.6 Study on the Antioxidant Activity of Smilax glabra in Vitro
[0078] 2.6.1 Determination of DPPH free radical scavenging ability
[0079] Preparation of sample solution: Prepare sample solution according to the method under "2.3", and dilute it with 70% methanol to different mass concentrations of sample solution. Take an appropriate amount of VC reference substance, weigh it accurately, dissolve it with 70% methanol, and dilute it to concentrations of 1, 2, 5, 10, 15, 20 μg·mL -1 solution as a positive control.
[0080] Preparation of DPPH solution: Take an appropriate amount of DPPH, dissolve it in anhydrous ethanol and prepare it to a mass concentration of 0.08 mg·mL -1 of DPPH solution.
[0081] Take 100 μL of sample solution and reference solution of different mass concentrations, place in a 96-well plate, add 150 μL of DPPH solution to each well, mix well, incubate in a 37°C water bath away from light for 30 minutes, and use an enzyme reader to measure the absorbance A1 at 517 nm; the blank group uses 70% methanol instead of the sample solution to measure its absorbance A0; the control group uses 70% methanol instead of DPPH solution to measure its absorbance A2. Set up 3 replicate wells for each group and take the average value. According to the following formula
[15] Calculate the scavenging rate: DPPH free radical scavenging rate = [1-(A1-A2) / A0] × 100%. GraphPad Prism 8.3.0 software was used to calculate the scavenging rate based on the sample concentration (mg·mL -1 ) as the horizontal axis and the clearance rate as the vertical axis, logarithmic curve fitting was performed to obtain the fitting formula and calculate its half maximal inhibitory concentration (IC 50 ), see Table 10. IC 50 The value is inversely proportional to the antioxidant capacity. The larger the value, the weaker the antioxidant capacity. The results showed that Smilax glabra from different sources had a certain DPPH free radical scavenging effect, and the free radical scavenging ability increased with the increase of concentration. 50 0.1138~3.5160mg·mL -1 Among them, S7 (Yunnan), S17 (Hubei), and S16 (Hunan) had stronger abilities to scavenge DPPH free radicals.
[0082] Table 10 IC of antioxidant activity of Smilax glabra 50 (mg·mL -1 , x±s, n=3)
[0083]
[0084]
[0085] 2.6.2 Determination of ABTS free radical scavenging ability
[0086] Preparation of sample solution: Prepare sample solution according to the method under "2.3", and dilute it with 70% methanol to different mass concentrations of sample solution. Take an appropriate amount of VC reference substance, accurately weigh it, dissolve it with 70% methanol, and dilute it to concentrations of 0.05, 0.1, 0.15, 0.20, 0.22, and 0.25 mg·mL -1 solution as a positive control.
[0087] According to the instructions of the ABTS kit, the sample solution was added to the 96-well plate in sequence, and then the ABTS working solution was added. The reaction was carried out at room temperature in the dark for 6 minutes, and the absorbance A1 was measured at 405nm; the blank group used 70% methanol instead of the sample solution, and its absorbance A0 was measured; the control group used 70% methanol instead of the ABTS free radical working solution, and its absorbance A2 was measured. Three replicate wells were set for each group, and the average value was taken. The clearance rate was calculated according to the following formula: ABTS free radical clearance rate = [1-(A1-A2) / A0] × 100%. IC 50 The calculation method of the value is the same as that of "2.6.1", and the results are shown in Table 6. The scavenging effect of ABTS free radicals of 40 batches of Smilax glabra samples increased with the increase of concentration. 50 0.0592~5.2707mg·mL -1 Among them, S31 (Yunnan), S37 (Guangxi), and S39 (Guangxi) had stronger abilities to scavenge ABTS free radicals.
[0088] 2.7 Spectrum-effect relationship analysis
[0089] 2.7.1 Grey relational analysis (GRA)
[0090] In order to further explore the relationship between the common peaks of the fingerprint spectrum of Smilax glabra and its antioxidant activity, this study used GRA to analyze its spectrum-activity relationship. 50 The reciprocal of the value is taken as the parent sequence, and the peak area of each common peak is taken as the subsequence to form a data matrix. The data matrix is dimensionlessly quantified using the initial value method, and the resolution coefficient is taken as 0.5 for GRA analysis. The reference method
[16] , calculated the correlation between the common peaks of Smilax glabra and the antioxidant activity (see Table 11). The greater the correlation, the greater the influence of the comparison sequence on the reference sequence. The results showed that the correlation between the 19 common peaks and the antioxidant activity results was greater than 0.7, indicating that the antioxidant effect of Smilax glabra is affected by the combined action of multiple components.
[0091] Table 11 Correlation between common peaks of Smilax glabra and antioxidant activity
[0092]
[0093]
[0094] 2.7.2 Partial least squares regression (PLSR) analysis
[0095] In order to further clarify the spectrum-effect relationship between the components of Smilax glabra and the antioxidant activity, the peak areas and antioxidant activity data of 19 common peaks in 40 batches of Smilax glabra fingerprints were standardized and imported into SIMCA 14.1 software to calculate the standardized regression coefficient and variable importance in projection (VIP) value. A positive regression coefficient means that the peak area of the common peak is positively correlated with the antioxidant activity, and vice versa. Figure 6 VIP value represents the contribution of the variable. VIP>1 means that the variable has a significant impact on the model. Figure 7 VIP>1 and positively correlated with DPPH free radical scavenging ability were chromatographic peaks 3, 5, 6, 7, 9, 11, 13-19; VIP>1 and positively correlated with ABTS free radical scavenging ability were chromatographic peaks 6, 9-11, 14-16, 19. This indicates that the compounds represented by these characteristic peaks play an important role in the antioxidant effect of Smilax glabra.
[0096] Based on the results of GRA and PLSR analysis, the characteristic peaks of antioxidant effects of different batches of Smilax glabra were screened out, which may be peak 6 (epicatechin), peak 9, peak 11, peak 14, peak 15 (neoisastilbin), peak 16 (isoastilbin) and peak 19.
[0097] 3 Discussions
[0098] 3.1 Investigation of chromatographic and extraction conditions
[0099] In the early stage of this study, the effects of the extraction solvent (50% methanol, 60% methanol, 70% methanol, 80% methanol, 90% methanol), extraction method (ultrasound, reflux), mobile phase composition (acetonitrile-0.1% glacial acetic acid aqueous solution, acetonitrile-0.1% formic acid aqueous solution, acetonitrile-0.1% phosphoric acid aqueous solution, acetonitrile-0.05% phosphoric acid aqueous solution, acetonitrile-0.01% phosphoric acid aqueous solution, methanol-0.05% phosphoric acid aqueous solution) and other conditions on the chromatographic peaks were investigated. The results showed that when 70% methanol was used for extraction, there were more chromatographic peaks and higher peak response values. When gradient elution was performed with acetonitrile-0.05% phosphoric acid aqueous solution as the mobile phase, the peak shape and separation of each chromatographic peak were good. In addition, the test solution of Smilax glabra was scanned at full wavelength (190-400nm), and it was found that many components had good absorption at a wavelength of 220nm. Therefore, 220nm was finally determined as the detection wavelength.
[0100] 3.2 Analysis of fingerprints and in vitro antioxidant activity results
[0101] The HPLC fingerprint results of 40 batches of Smilax glabra showed that the chemical components of Smilax glabra from different origins were basically the same, but the contents were different. Among them, the similarities of samples S36 (0.572), S40 (0.358) and S37 (0.990) from the same origin were quite different, and the similarities between S6 and S7 from different origins were also low, which may be related to factors such as different geographical environments, harvesting and processing.
[0102] In addition, the antioxidant activity of Smilax glabra was evaluated by DPPH method and ABTS method. By analyzing its free radical scavenging ability, it was found that different batches of Smilax glabra had certain antioxidant activity, and the size of its antioxidant activity may be related to the different contents of active ingredients. S27, S28, and S39 were clustered into Class II in HCA and PCA analysis, and their antioxidant activities were strong in both DPPH and ABTS methods. Batch S14 was clustered into Class I in HCA and PCA analysis, with strong ability to scavenge DPPH free radicals, but weak antioxidant activity in the ABTS method. The differences in performance of each batch may be caused by the different reaction mechanisms of the ingredients contained and different determination methods, so combining the two for analysis can more objectively evaluate the antioxidant activity of Smilax glabra.
[0103] 3.3 Spectrum-effect relationship analysis
[0104] In this study, the correlation between the 19 common peaks in the fingerprint of Smilax glabra and the antioxidant activity was greater than 0.7, and the correlation between each batch and the efficacy index was not much different, indicating that the 19 common peaks and the two variables of antioxidant capacity were highly correlated, which shows that the antioxidant activity of Smilax glabra is the result of the synergistic effect of multiple components. In the PLSR analysis, the common peaks that contribute most to the scavenging free radicals of DPPH and ABTS are peak 6 (epicatechin), peak 9, peak 11, peak 14, peak 15 (neoisoastilbin), peak 16 (isoastilbin) and peak 19. The results obtained by the two antioxidant methods are basically consistent, and the antioxidant active ingredients contained in Smilax glabra are relatively stable in both methods. Combining the results of GRA and PLSR, it is concluded that the antioxidant active ingredient group of Smilax glabra is epicatechin, neoisoastilbin, isoastilbin, etc.
[0105] In summary, the HPLC fingerprint method of Smilax glabra established in this study is reliable, stable and reproducible. Spectrum-activity analysis was carried out in combination with its antioxidant activity, and epicatechin, neoisoltin, isosilbin and other components were screened out as the main potential antioxidant active ingredients of Smilax glabra, which provides a reference basis for the quality control and evaluation research of Smilax glabra and lays the foundation for its subsequent development and utilization.
Claims
1. An HPLC fingerprint of a Chinese smilax glabra medicinal material, characterized in that When the HPLC chromatographic conditions are as follows, the HPLC fingerprint of the Smilax glabra medicinal material is substantially consistent with FIG1 ; HPLC chromatographic conditions are as follows: The chromatographic column is Agilent 5TC-C 18 , specifications: 250mm×4.6mm, 5μm; Mobile phase: acetonitrile as phase A, 0.05wt% phosphoric acid aqueous solution as phase B; Gradient elution: 0-16 min, phase A volume percentage of 6% → 14%; 16-28 min, phase A volume percentage of 14% → 16%, 28-32 min, phase A volume percentage of 16%, 32-42 min, phase A volume percentage of 16% → 18%; 42-48 min, phase A volume percentage of 18%, 48-56 min, phase A volume percentage of 18% to 23%, 56-62 min, phase A volume percentage of 23%, 62-70 min, phase A volume percentage of 23% to 30%, 70-80 min, phase A volume percentage of 30%; flow rate: 0.8 mL min -1 ; Column temperature: 30°C; detection wavelength: 220nm; injection volume: 10μL.
2. The HPLC fingerprint of the Smilax glabra medicinal material according to claim 1 is characterized in that The HPLC fingerprint of the Chinese smilax glabra medicinal material is basically consistent with Figure 1, and has no less than 19 characteristic fingerprint chromatographic peaks, among which peak No. 2 is catechin, peak No. 6 is epicatechin, peak No. 8 is 5-O-caffeoylshikimic acid, peak No. 12 is neoastilbin, peak No. 13 is astilbin, peak No. 15 is neoisoastilbin, peak No. 16 is isoastilbin, peak No. 17 is flavonoids glycoside, and peak No. 18 is resveratrol.
3. The HPLC fingerprint of the Smilax glabra medicinal material according to any one of claims 1 to 2 is characterized in that Taking the retention time of peak 8 as a reference, the relative retention times of peaks 2, 6, 12, 13, 15, 16, 17, and 18 in the HPLC fingerprint of Smilax glabra are shown in the following table:
4. Application of the HPLC fingerprint of the Smilax glabra medicinal material according to any one of claims 1 to 3 in quality control and component analysis of the Smilax glabra medicinal material.
5. Application of the HPLC fingerprint of the Smilax glabra medicinal material according to any one of claims 1 to 3 in the quality control of the Smilax glabra medicinal material, characterized in that The application comprises the following steps: (1) Grinding the Chinese smilax glabra medicinal material and then ultrasonically extracting it to prepare a test solution; (2) taking the test sample solution obtained in step (1), and testing it by HPLC to obtain an HPLC chart of the test sample; (3) Compare the HPLC chromatogram of the test sample obtained in step (2) with the HPLC fingerprint of the Smilax glabra medicinal material described in the present invention. The Smilax glabra medicinal material with a similarity of more than 0.81 is a qualified product.
6. The use according to claim 5, characterized in that The preparation method of the test solution described in step (1) is as follows: grind the Chinese smilax glabra medicinal material, pass it through a 40-mesh sieve, weigh 0.5 g, place it in a stoppered conical flask, accurately add 10 ml of 70% methanol by volume, seal it, weigh it, treat it with ultrasound for 30 minutes, let it stand and cool to room temperature, weigh it again, make up the weight loss with 70% methanol by volume, shake it well, filter it, and take the filtrate through a 0.45 μm microporous filter membrane to obtain it.
Citation Information
Cited By
Construction method and application of fingerprint spectrum based on ganoderma lucidum antioxidant active components
CN119936248A
Method for constructing fingerprint on the basis of ganoderma lucidum antioxidant active components and use thereof
WO2026157346A1
